Announced
Completed
Financials
Tags
Majority
Acquisition
Domestic
biotechnology
Private
Single Bidder
Friendly
Biotechnology
United States
Completed
Synopsis
Ginkgo Bioworks, a platform for cell programming and biosecurity, completed the acquisition of the AAV capsid discovery and engineering platform assets of StrideBio, a gene therapy company. Financial terms were not disclosed. "Combining Ginkgo's engineering and discovery capabilities in enzymes, regulatory elements, and capsids enables a holistic approach to designing an AAV gene therapy, so that we can support our partners across the entire process of designing the viral vector. We are thrilled to integrate the STRIVE platform and know-how into our foundry to augment our capabilities in capsid engineering, and we look forward to continuing to expand our existing end-to-end capabilities in AAV discovery and manufacturing," Narendra Maheshri, Ginkgo Head of Mammalian Engineering.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.